|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
UK MOD Signs Protector Support Contract with GA-ASI
Jun 10, 2025 06:00 HKT/SGT
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 21:58 HKT/SGT
|
|
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 9, 2025 20:30: JST
|
|
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 9, 2025 19:30 HKT/SGT
|
|
|
SRKay Consulting Group Releases Research Report: 'From Legal Frameworks to Successful Operations'--A Strategic Playbook for India Market Entry
Jun 9, 2025 17:00 HKT/SGT
|
|
|
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑
Jun 9, 2025 12:47 HKT/SGT
|
|
|
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径
Jun 9, 2025 12:35 HKT/SGT
|
|
|
光大控股成功發行30億元人民幣熊貓中期票據
Jun 9, 2025 10:07 HKT/SGT
|
|
|
光大控股成功发行30亿元人民币熊猫中期票据
Jun 9, 2025 10:00 HKT/SGT
|
|
|
冠君产业信托呈献“Lupus Reimagined”艺术展 以艺术连结社区 共创多元共融未来
Jun 6, 2025 19:22 HKT/SGT
|
|
|
Champion REIT Presents 'Lupus Reimagined' Art Exhibition, Connecting Community Through Art
Jun 6, 2025 18:55 HKT/SGT
|
|
|
冠君產業信託呈獻「Lupus Reimagined」藝術展 以藝術連結社區 共創多元共融未來
Jun 6, 2025 18:23 HKT/SGT
|
|
|
稀有中高端冷冻海产上市公司大洋环球上月跑赢大市 最新财报有启示？
Jun 6, 2025 16:16 HKT/SGT
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 16:00: JST
|
|
|
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 6, 2025 16:42 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
